Different outcomes among favourable and unfavourable intermediate-risk prostate cancer patients treated with hypofractionated radiotherapy and androgen deprivation therapy

Table 1 Patients’ characteristics

Characteristics	FIR (n = 49)		UIR (n = 82)		Total (n = 131)		p value
	n.	%	n.	%	n.	%
Age
Median (range)	74	(55–84)	74	(53–88)	74	(53–88)	0,39
< 75 years	28	57,1	41	50,0	69	52,7	0,43
≥ 75 years	21	42,9	41	50,0	62	47,3	0,43
PSA at diagnosis
Median (range)	9,6	(0,9–19,0)	8,5	(0,9–19,99)	9,0	(0,9–19,9)	0,72
< 10 ng/mL	24	51,1	46	56,8	70	54,7	0,53
10–19,9 ng/mL	23	48,9	35	43,2	58	45,3	0,53
Clinical T stage
T1c	16	32,7	13	15,9	29	22,1	<0.001
T2a	32	65,3	23	28,0	55	42,0
T2b	1	2,0	27	32,9	28	21,4
T2c	0	0	19	23,2	19	14,5
Biopsy Gleason score
3 + 3	26	53,1	9	11,0	35	26,7	<0.001
3 + 4	23	46,9	44	53,7	67	51,1
4 + 3	0	0	29	35,4	29	22,1
PPBCs
< 50 %	49	100	39	47,6	88	67,2	<0,001
≥ 50 %	0	0	43	52,4	43	32,8	<0,001
IRFs
< 2	49	100	23	28,0	72	55,0	<0,001
≥ 2	0	0	59	72,0	59	45,0	<0,001
HT
Antiandrogen	32	65,3	56	68,3	88	67,2	0,72
LHRH analogue	17	34,7	26	31,7	43	32,8	0,72

ISSN: 1748-717X